Glucocorticoid Receptor Suppresses Tumor Formation by Ensuring Accurate Chromosome Segregation During Mitosis
|
By LabMedica International staff writers Posted on 20 Apr 2015 |

Image: Electrophoretic data confirmed disruption of mitosis in cells lacking GR (Photo courtesy of the University of Manchester).
A team of British molecular biologists has defined the mechanism by which glucocorticoid receptor (GR) regulates the process of mitosis to prevent errors in cell division that could lead to tumor formation.
GR is a member of the nuclear receptor superfamily, which controls programs regulating cell proliferation, differentiation, and apoptosis. GR is expressed in almost every cell in the body and regulates genes controlling development, metabolism, and immune response. As the receptor gene is expressed in several forms, it has many different effects in various parts of the body. Unbound receptor resides in the cytosol of the cell. Binding of GR to glucocorticoids triggers its primary mechanism of action, which is the regulation of gene transcription. After the receptor is bound to glucocorticoid, the receptor-glucorticoid complex up-regulates the expression of anti-inflammatory proteins in the nucleus or represses the expression of pro-inflammatory proteins in the cytosol (by preventing the translocation of other transcription factors from the cytosol into the nucleus).
Investigators at the University of Manchester (United Kingdom) identified an additional role for GR related to regulation of cell division. They discovered that specifically modified GR species accumulated at the mitotic spindle during mitosis in a distribution that overlapped with enzymes of the Aurora kinase family. They found that Aurora A was required to mediate mitosis-driven GR phosphorylation, but not recruitment of GR to the spindle. GR was necessary for mitotic progression, with increased time to complete mitosis, frequency of mitotic aberrations, and death in mitosis observed following GR knockdown. Complementation studies revealed an essential role for the GR ligand-binding domain, but no clear requirement for ligand binding in regulating chromosome segregation.
GR haploinsufficient mice (animals with only a single functional copy of the GR gene that did not produce enough of the gene product to bring about the wild-type condition) had an increased incidence of tumor formation, and these tumors were further depleted for GR, implying additional GR loss as a consequence of cell transformation. Reduced GR expression was identified in a panel of human liver, lung, prostate, colon, and breast cancers.
The unexpected role for the GR in promoting accurate chromosome segregation during mitosis marked GR as an authentic tumor suppressor gene. "Cancer is caused by cell division going wrong, but no one has previously looked at the role GR has to play in this process," said senior author Dr. David Ray, professor of human development at the University of Manchester. "It is now clear that it is vital."
The study was published in the April 6, 2015, online edition of the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS).
Related Links:
University of Manchester
GR is a member of the nuclear receptor superfamily, which controls programs regulating cell proliferation, differentiation, and apoptosis. GR is expressed in almost every cell in the body and regulates genes controlling development, metabolism, and immune response. As the receptor gene is expressed in several forms, it has many different effects in various parts of the body. Unbound receptor resides in the cytosol of the cell. Binding of GR to glucocorticoids triggers its primary mechanism of action, which is the regulation of gene transcription. After the receptor is bound to glucocorticoid, the receptor-glucorticoid complex up-regulates the expression of anti-inflammatory proteins in the nucleus or represses the expression of pro-inflammatory proteins in the cytosol (by preventing the translocation of other transcription factors from the cytosol into the nucleus).
Investigators at the University of Manchester (United Kingdom) identified an additional role for GR related to regulation of cell division. They discovered that specifically modified GR species accumulated at the mitotic spindle during mitosis in a distribution that overlapped with enzymes of the Aurora kinase family. They found that Aurora A was required to mediate mitosis-driven GR phosphorylation, but not recruitment of GR to the spindle. GR was necessary for mitotic progression, with increased time to complete mitosis, frequency of mitotic aberrations, and death in mitosis observed following GR knockdown. Complementation studies revealed an essential role for the GR ligand-binding domain, but no clear requirement for ligand binding in regulating chromosome segregation.
GR haploinsufficient mice (animals with only a single functional copy of the GR gene that did not produce enough of the gene product to bring about the wild-type condition) had an increased incidence of tumor formation, and these tumors were further depleted for GR, implying additional GR loss as a consequence of cell transformation. Reduced GR expression was identified in a panel of human liver, lung, prostate, colon, and breast cancers.
The unexpected role for the GR in promoting accurate chromosome segregation during mitosis marked GR as an authentic tumor suppressor gene. "Cancer is caused by cell division going wrong, but no one has previously looked at the role GR has to play in this process," said senior author Dr. David Ray, professor of human development at the University of Manchester. "It is now clear that it is vital."
The study was published in the April 6, 2015, online edition of the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS).
Related Links:
University of Manchester
Latest BioResearch News
- Immune Biomarkers Support Early Risk Stratification in Oral Precancer
- Global Genetic Map Identifies Regional Parkinson’s Variants to Support Diagnostics
- Breakthrough Genetic Map Advances Understanding of Bone Disorders
- Study Identifies Hereditary Subtype of Aggressive Prostate Cancer
- Gene Variants Linked to Pollution-Exacerbated Asthma
- Single-Cell Analysis Mapping Links Inflammation Response to Acute Myeloid Leukemia
- Study Reveals New Insights into Rare Blood Cancer Development
- New Findings Clarify Molecular Drivers of Rare Small Intestinal Cancer
- Lung Cancer Study Reveals Cellular Program Behind Therapy Resistance
- Tumor Genome Marker May Predict Treatment Benefit in Pediatric Cancers
- Lysosomal Gene Defect Linked to Severe Childhood Brain Disorders
- Genetic Testing Identifies Greater Inherited Sudden Cardiac Arrest Risk in Younger Individuals
- Hidden 'Jumping Gene' Variant Linked to Higher Pancreatic Cancer Risk
- Common White Blood Cells Produce Schizophrenia-Linked Protein
- Nanopore Method Captures RNA Folding at Single-Molecule Resolution
- Tumor Microenvironment Marker Linked to Worse Survival in Solid Tumors
Channels
Clinical Chemistry
view channel
New Machine-Learning Equation Improves LDL Cholesterol Assessment
Accurate assessment of low-density lipoprotein (LDL) cholesterol is central to cardiovascular risk management, yet calculation methods can underestimate values in some patients. Laboratories widely use... Read more
Blood Biomarker May Signal Cognitive Decline Risk a Decade Before Symptoms
Accurately identifying which cognitively healthy older adults will later develop impairment due to Alzheimer’s disease remains difficult, as brain scans and genetic testing provide only part of the risk picture.... Read moreMolecular Diagnostics
view channel
New Biomarker Helps Guide Combination Therapy for Treatment-Resistant Breast Cancer
Chemotherapy resistance hampers treatment of triple-negative breast cancer (TNBC), particularly in tumors with TP53 mutations. Identifying biomarkers that signal resistance while pointing to actionable... Read moreBlood-Based Gene Expression Test Detects Early Pancreatic Cancer
Pancreatic cancer remains difficult to detect at a curable stage and is associated with poor survival outcomes. In Japan, the five-year relative survival rate is 8.5%, while early-stage disease accounts... Read moreHematology
view channel
New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more
AI Decision Support System Guides Treatment Selection for Complex Blood Cancers
Treatment selection for hematologic malignancies often requires clinicians to synthesize clinical histories, genomic alterations, prior therapies, and rapidly evolving drug options. These complex decisions... Read moreImmunology
view channel
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read more
Cell-Free Assay Detects Functional IgE for Food Allergy Diagnosis
Accurately distinguishing sensitization from clinically relevant food allergy remains a challenge for laboratories, as routine blood tests detect allergen-specific immunoglobulin E (IgE) but not its capacity... Read more
Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19
Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more
Anti-Lipid Antibody Biomarkers May Identify Early Lyme Disease and Persistent Symptoms
Lyme disease is often missed during its earliest and most treatable stage, while current serologic assays cannot distinguish active infection from prior exposure. Nearly half a million Americans are diagnosed... Read moreMicrobiology
view channel
Syndromic GI Panel Detects Cyclospora for Rapid Case Confirmation
U.S. health authorities have reported a rapid increase in cyclosporiasis since May 2026, with more than 1,600 confirmed infections and thousands of additional suspected cases under investigation.... Read more
Rapid Panel Identifies Gram-Negative Pathogens and Resistance Markers in Bloodstream Infections
Bloodstream infections require rapid identification of causative pathogens and resistance mechanisms to guide effective therapy. Delays in profiling gram-negative organisms, which are frequently associated... Read morePathology
view channel
AI Bone Marrow Mapping Provides New Tool to Track Blood Cancer Severity
Myelodysplastic neoplasms, a group of blood cancers that primarily affect older adults, are challenging to stage and monitor, often requiring repeated bone marrow biopsies that can yield uncertain interpretations.... Read more
Imaging Platform Maps Lipid Accumulations in Fabry Heart Tissue
Mapping the spatial distribution of disease-relevant molecules within tissue remains a diagnostic challenge, particularly before alterations are visible by conventional microscopy. In Fabry disease, a... Read moreTechnology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Leica Biosystems to Expand Pathology Portfolio Through StatLab Acquisition
Leica Biosystems, an operating company of Danaher, has entered into a definitive agreement to acquire privately held StatLab Medical Products from Linden Capital Partners and Audax Private Equity.... Read more




.jpg)



